Pediatric research
Impact on mortality of inhaled nitric oxide in newborns ≤34 weeks with early hypoxemic respiratory failure: systematic review and meta-analysis
Von Alvarado-Socarras JL, Theurel-Martín DE und Manrique-Hernández EF.
Inhalt auf Englisch
Abstract
Introduction
Inhaled nitric oxide (iNO) is approved for hypoxemic respiratory failure (HRF) associated with pulmonary hypertension (PH) in term and near-term neonates; however, its use in preterm infants ≤34 weeks' gestation remains controversial, with limited and inconsistent evidence of survival benefit.
Objective
To evaluate the association between iNO use and mortality in preterm neonates ≤34 weeks' gestation.